Skip to content

Author

Jonathan R. Brody

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract B122: The timing matters: schedule-dependent optimization of gemcitabine and RAS(ON) inhibition in pancreatic cancer, a call for a new approach to clinical trial design

It is shown that GEM followed by RAS inhibitor (GEM→RASi) scheduling is associated with improved survival and altered tumor growth dynamics relative to reverse scheduling and monotherapies, and favorable survival trends compared to concurrent treatment, with reduced total agent exposure.

Jonathan R. Brody · 0 citations
Sep 2026

The post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma.

Overall, it is found that the post-transcriptional regulator HuR facilitates immune evasion in PDAC by constraining T-cell function, identifying HuR blockade as a promising therapeutic strategy in combination with immunotherapies.

Yi-Fei Guo, Jennifer M. Finan, Alexandra Q. Bartlett et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.